Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000248045 | SCV000308872 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Illumina Laboratory Services, |
RCV000263355 | SCV000399960 | benign | Melanoma, cutaneous malignant, susceptibility to, 5 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign. |
Labcorp Genetics |
RCV000263355 | SCV001730600 | benign | Melanoma, cutaneous malignant, susceptibility to, 5 | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001683032 | SCV001899163 | benign | not provided | 2018-06-22 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 22547573, 30414346, 30531825, 29178624, 11487574, 21052032, 24335900, 22854540, 18366057, 17616515, 11875032, 23711066, 24660985, 23647022, 22464597) |
Fulgent Genetics, |
RCV002500893 | SCV002809656 | benign | Tyrosinase-positive oculocutaneous albinism; Skin/hair/eye pigmentation, variation in, 2; Increased analgesia from kappa-opioid receptor agonist, female-specific; Melanoma, cutaneous malignant, susceptibility to, 5 | 2022-04-14 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001683032 | SCV005249038 | benign | not provided | criteria provided, single submitter | not provided |